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Abstract
For the healthcare sector, it is critical to exploit the vast amount of textual health-related information. Nevertheless,
healthcare providers have diculties to benet from such quantity of data during pharmacotherapeutic care. The
problem is that such information is stored in dierent sources and their consultation time is limited. In this context,
Natural Language Processing techniques can be applied to eciently transform textual data into structured information
so that it could be used in critical healthcare applications, being of help for physicians in their daily workload, such as:
decision support systems, cohort identication, patient management, etc. Any development of these techniques requires
annotated corpora. However, there is a lack of such resources in this domain and, in most cases, the few ones available
concern English.
This paper presents the denition and creation of DrugSemantics corpus, a collection of Summaries of Product Char-
acteristics in Spanish. It was manually annotated with pharmacotherapeutic named entities, detailed in DrugSemantics
annotation scheme. Annotators were a Registered Nurse (RN) and two students from the Degree in Nursing. The
quality of DrugSemantics corpus has been assessed by measuring its annotation reliability (overall F=79.33% [95%CI:
78.35-80.31]), as well as its annotation precision (overall P = 94:65% [95%CI: 94.11-95.19]). Besides, the gold-standard
construction process is described in detail. In total, our corpus contains more than 2,000 named entities, 780 sentences
and 226,729 tokens. Last, a Named Entity Classication module trained on DrugSemantics is presented aiming at
showing the quality of our corpus, as well as an example of how to use it.
Keywords: Corpus, Reliability, Precision, Named Entity Recognition, Spanish, Summary of Product Characteristics
1. Introduction
Nowadays, there is a large amount of information on
health and healthcare [1]. Examples of this huge quantity
of information available are PubMed [2], a repository that
comprises more than 25 million documents on biomedical
literature, or the information stored for each patient on
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correos 99, E-03080 Alicante, Spain. Tel: +34965903400 ext. 2340
Email addresses: imoreno@dlsi.ua.es (Isabel Moreno),
eboldrini@dlsi.ua.es (Ester Boldrini), moreda@dlsi.ua.es
(Paloma Moreda), mtr.ferri@ua.es (M. Teresa Roma-Ferri)
its own Electronic Health Record (EHR) during day-to-
day care. Due to the high value of such data, exploiting
this textual information is critical to: (i) improve health-
care quality; (ii) drive medical innovation research; and
(iii) reduce healthcare costs [1]. Nevertheless, healthcare
providers have diculties to use such quantity of informa-
tion during their professional practice mainly due to two
reasons. On the one hand, they have a limited consulta-
tion time (i.e. often less than 10 minutes). On the other
hand, the required information by them is stored in many
and dierent sources [3].
Preprint submitted to Journal of Biomedical Informatics April 24, 2017
  
Figure 1: Example of an hypothetical tool (center box) to allow pharmacoterapeutic monitoring using Natural Language Processing techniques,
as in the example described in Section 1 Introduction. Its input is raw content (left box) and its output is structured content (right box).
Envision yourself in a primary health care consultation.
A general physician attends to a patient that shows sev-
eral health problems, for instance: overweight, diabetes
and hypercholesterolemia. This patient is being moni-
tored with diet, exercise and various medications but, dur-
ing check-ups monitoring, he/she is not improving. The
physician needs to know whether the negative evolution of
his/her weight and his/her cholesterol are related or not to
the medications employed for his/her treatment (an oral
hypoglycemic and a lipid-regulating agents).
Before reaching a conclusion, the physician should anal-
yse a wide range of specialized documents of dierent sizes
and sources. The most relevant ones are: (i) patient EHR,
accessible through many and dierent applications; (ii)
Summaries of medicinal Product Characteristics (SPC)
or package leaets for the patients medications, available
on medicines agencies web sites at international1 or na-
tional2 levels; and (iii) scientic papers indexed in biomed-
1European Medicines Agency has more than 937 authorised med-
ications - January 2017 (http://www.ema.europa.eu/).
2Spanish Agency of Medicines and Medical Devices contains
ical bibliographic databases, such us MEDLINE [2]3, or
Scopus [4]4. For healthcare providers, the analysis of all
the information contained in every information source is
unmanageable [5{7]. Thus they would need a tool that dis-
plays, at a glance, every document relevant to the patient
condition with a single query based on their information
needs [8].
Natural Language Processing (NLP) is a eld of research
that addresses the obstacles mentioned above. Its aim is
to provide mechanisms to transform unstructured textual
information, easy to understand for humans, into struc-
tured data that can be exploited by computer processes
for dierent purposes [1, 9]. So, NLP techniques can be
employed to achieve the aforementioned tool for healthcare
providers. Figure 1 illustrates how to solve this problem
using NLP: rst, Information Retrieval (IR) techniques
more than 13,500 medications on the market - January 2017
(http://www.aemps.gob.es/).
3MEDLINE comprises more than 26 million citations (January
2017).
4Scopus includes more than 60 million records from journals and
books (January 2017).
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could be applied. In this way, relevant documents, that
satisfy an information need, could be found from a large
collection of documents [10, p. 1]. In our pharmacothera-
peutic monitoring example, relevant documents would be
the patient EHR together with SPCs and scientic papers
related to the patient's condition. Afterwards, Informa-
tion Extraction (IE) techniques could be employed. In this
manner, textual and explicit relevant information could
be extracted from the retrieved documents in the previous
step [11, pp. 94-95][12, pp. 814-815]. In our example, the
relevant information could be all the medication that a pa-
tient is currently taking and his symptoms (from the EHR)
as well as signs commonly associated to these medications
(from SPCs and scientic papers), among other relevant
information. Then, Text Mining (TM) techniques could be
used. This area is in charge of nding information that is
not specied explicitly in the document, therefore, further
inference is needed [13]. In the case we are dealing with, it
would be to discover a reason for the negative evolution of
weight and cholesterol level. That is, whether the patients
current medication, all of which have been extracted pre-
viously from explicit information, is interacting with each
other or not. Finally, all the obtained information (both
explicit and implicit) would be displayed in an organized
and summarized manner to the physician, in order to fa-
cilitate reaching a conclusion.
Building such tool for healthcare providers is not a triv-
ial task. This is because IR is a mature area [5, 14] where
several IR systems have been developed to retrieve docu-
ments that satises an user's information need. Some ex-
amples are PubMed [2] (professional level) or Google [15]
(wide variety of users). However, there is still plenty of
work to do, in both IE and TM techniques, to reach suit-
able results for many and dierent user proles [16].
Progress in any of these techniques relies heavily on an-
notated corpora.This is due to the fact that these resources
have mainly two purposes: (i) development - to assist dur-
ing the creation of rules and statistical models that will
control the behaviour of a system; and (ii) evaluation - to
provide reference data against which to assess the perfor-
mance of a system. Nevertheless, annotated corpora for
the health domain present two main barriers.
On the one hand, there is a limited number of annotated
corpora [17] and existing ones do not consider all relevant
information for pharmacotherapeutic care, as Section 2
will show. Therefore, the goal of our research is the con-
struction of DrugSemantics, a pharmacotherapeutic cor-
pus to tackle a part of the IE problem. This resource
contains annotations of Named Entities (NE) relevant to
the pharmacotherapeutic care. A NE represents a men-
tion of a semantic category in a text [11, 18]. In this
eld, these NEs categories refer to important information
for the prescription and monitoring processes of pharma-
ceutical products [3, 19] and relates to concepts such as
medicines5 or clinical conditions6.
On the other hand, most eorts have been focused
on English corpora construction [20]. For this reason,
DrugSemantics is a resource created using Spanish doc-
uments. It represents an attempt to increase the available
annotated corpora in this language to be used to detect
NEs. This corpus consists of SPCs, a type of document
that allows us to overcome limitations regarding patient
privacy and access to EHR data for researches outside the
healthcare institutions.
This paper has four objectives: (i) to describe the con-
struction of a gold standard, DrugSemantics, which con-
tains pharmacotherapeutic NEs; (ii) to report on agree-
ment between annotators, that is, reliability when a se-
mantic category (i.e. NE) is assigned to a relevant tex-
tual fragment from DrugSemantics corpus; (iii) to provide
precision of the semantic category assigned that means
whether relevant information found in DrugSemantics cor-
5For example: trade names of medicines (\Conacetol R") or ac-
tive substances (\Paracetamol" - acetaminophen in English).
6For instance: therapeutic indications, contraindications or inter-
current illness.
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pus is valid or not; and (iv) to demonstrate how to use the
DrugSemantics gold standard to deal with NEs.
The rest of the paper is organized as follows. Sec-
tion 2 describes previous eorts to build annotated cor-
pora. Then, Section 3 presents the materials and methods
employed during the construction of DrugSemantics cor-
pus and the quality evaluation of the created gold stan-
dard. Next, Section 4 outlines assessment results. Latter,
the achieved results are discussed in Section 5. Finally,
Section 6 presents our main conclusions.
2. Background
This section reviews existing corpora semantically anno-
tated with NEs that are relevant for pharmacotherapeu-
tic care. Building such resources for English has received
considerable attention [21{35]. The most relevant ones are
described below:
1. The i2b2 corpus [25{27] consists of 1,243 fully de-
identied discharge summaries from Partners Health-
care. This corpus was pre-annotated on the basis of
pooled system outputs [18], then 20.19% out of them
(i.e. a subset of 251) was manually checked by i2b2
challenge participants (NLP experts) and organizers
(domain experts and no experts trained). This cor-
pus includes medications (covering also active sub-
stances), dosages, frequencies, durations, routes and
reasons of administration.
2. The DrugDDI corpus [24] is made of 1,025 texts
from two dierent sources: MedLine [2] abstracts and
DrugBank [36] documents describing drug interac-
tions. All of these (100%) were pre-annotated au-
tomatically with UMLS MetaMap Transfer (MMTx)
tool [21]. Then two expert pharmacists, with back-
ground in pharmacovigilance, reviewed these tags and
added new ones, if necessary. This collection con-
tains: generic drug names (i.e. active substances),
branded drug names (i.e. medications), drug group
names (i.e. pharmatherapeutic group names) and ac-
tive substances not approved for human use. On aver-
age, each document contains 6.63 sentences and 18.05
NEs.
3. The CLEF corpus [23] has 565,000 documents of three
types: clinical narratives, histopathology reports and
imaging reports. These documents belong to 20,324
deceased patients from Royal Mardsen Hospital. Only
0.27% of these documents (i.e. a subset of 150) were
manually labelled by domain experts and NLP ex-
perts. The following NEs were included: condition
(i.e. disease), drug or device (i.e. medications, active
substances, etc.), intervention, investigation, result,
and locus. These documents contain 21.63 NEs on
average.
In contrast, it was not until recently when Spanish re-
searchers have created corpora related to the pharma-
cotherapeutic eld with semantic information in Spanish.
To the best of our knowledge, there are only two available:
1. The IxaMedGS [20] corpus contains 142,154 de-
identied Discharge Records of EHR written in Span-
ish from the Galdakao-Usansolo Hospital. Only 0.01%
of all records (i.e. a subset of 75) were pre-annotated
using Freeling-Med [20] to include: (i) diseases; and
(ii) drugs, namely: active substances and medicines.
After this, the result was manually checked by four
annotators, who have expertise in the Pharmacology
and Pharmacovigilance elds. On average, each doc-
ument contains 72.13 sentences, 555.11 tokens and
52.76 NEs.
2. The SpanishADRCorpus [37] is composed by 397 com-
ments gathered from a Spanish health forum, Forum-
Clinic [38]. Those comments (100%) were labelled
manually by two annotators with expertise in Phar-
macovigilance. This collection includes information
about the entities: (i) drugs (i.e. medicines, active
substances, pharmatherapeutic groups, etc.); and (ii)
4
  
adverse drug reactions. These documents contain
77.97 tokens 7 and 2.07 NEs on average.
A comparative summary of the analysed corpora, as
well as DrugSemantics gold standard, can be found in
Table 1. Regardless of the language, several conclusions
can be drawn. First, most eorts produced a semi-gold
standard corpus8, which could facilitate the manual an-
notation process by reducing time, as shown by [28, 39],
and task diculty. Second, all of them employed domain
experts due to their knowledge in this area. Third, all
corpora contain information about medications. Never-
theless, none of them include food or excipients, which
are also NEs critical when healthcare providers have to
choose a pharmacological treatment (e.g. to prevent in-
teraction and allergies problems) [3, 19]. Fourth, most of
them incorporate important clinical conditions: (i) condi-
tion [23]; (ii) reasons of administration [25{27]; (iii) dis-
eases [20]; and (iv) adverse drug reactions [37]. But other
clinical conditions, such as medical contraindications or
overdoses, are not explicitly incorporated and all of them
are essential in both medicine prescription and monitoring
processes during day-to-day care [3, 19].
Focusing on the dierences between the two languages,
corpora have been created more frequently for English [21{
35] than Spanish [20, 37]. The length of the annotated
documents is not shared between the languages: English
resources have a more balanced number of NE per docu-
ment (18.05 versus 21.63) than Spanish ones (52.76 ver-
sus 2.07). Furthermore, it should be noted that existing
Spanish corpora only include information about diseases,
adverse drug reactions and drugs, as Table 1 shows.
7Value computed using LingPipe Tokenizer plugin and pub-
licly available data at http://labda.inf.uc3m.es/doku.php?id=en:
labda_spanishadrcorpus (last access April 16, 2017). When using
LingPipe, the term token refers to all document units (e.g. terms
and punctuation symbols) except from spaces.
8A semi-gold standard corpus is created by a human annotator
who manually checks pre-annotated entities.
Given the identied gaps, this paper reports on the
construction of the Spanish DrugSemantics corpus, which
is designed to include a larger number of NEs for the
pharmacotherapeutic process than previous works.
3. Material and Methods
This section describes the methodology employed to
build the DrugSemantics corpus. First, the document
sampling procedure is presented in Section 3.1. Then,
our annotation scheme is outlined in Section 3.2. Lat-
ter, the manual annotation guidelines are described in Sec-
tion 3.3. Next, the assessment of the manual annotation
is dened. On the one hand, Section 3.4 presents the met-
rics of this evaluation. On the other hand, the method-
ology followed to compute these metrics is described in
Section 3.5. Lastly, the construction of the gold standard
is presented in Section 3.6.
3.1. DrugSemantics Corpus Sampling Description
This corpus consists of 30 Summaries of medicinal Prod-
uct Characteristics (SPC), which includes 7,085 sentences
and 175,965 tokens. SPC is an standardised ocial
document [40] that includes wealth information about a
medicine, approved by health authorities, and its thera-
peutic indications [41]. This type of document was cho-
sen due to two reasons: (i) SPCs cover appropriately
the information needs and they are a priority informa-
tion source for prescribing and monitoring medications, as
shown in [34, 42]; and (ii) health information from citi-
zens has limited access [1, 43{45] and, nowadays, there is
no Spanish open-access repository integrating de-identied
information on patients equivalent to Research Patient
Data Repository from Partners Healthcare [46].
The SPCs were selected from a reliable open-access
repository called \Medicines Online Information Cen-
ter" (CIMA[47]) that belongs to the Spanish Agency for
Medicines and Health Products (AEMPS). The aim of the
sampling was to consider medicines widely used in Spain
5
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Table 1: Features of the analysed corpora related to pharmacotherapy
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to treat elevated cholesterol levels, as well as to deal with
minor health problems, such as fever or mild to moder-
ate pain. Thus, a non-probabilistic sampling, using ex-
pert judgement, was manually performed to choose 5 ac-
tive substance, namely: Atorvastatin, Simvastatin, Acetyl-
salicylic Acid/Aspirin, Paracetamol/Acetaminophen and
Ibuprofen.
For each drug, 6 SPCs were chosen considering
only commercialized medicines at that time with dif-
ferent brand names (e.g. Gelocatil R or Paracetamol
Ratiopharm R) and pharmaceutical forms (e.g. capsules,
tablets) to ensure the highest diversity as possible. In
the case of medicines for cholesterol (i.e. Atorvastatin
and Simavastatin), the variability is lower because only
two pharmaceutical forms are used (i.e. tablets and lm-
coated tablets). Finally, it should be noted that medicines
whose active substance is Atorvastatin are mainly generic.
Therefore, according to current Spanish regulations, its
brand name must include the active substance name [40]
(e.g. Paracetamol Ratiopharm R).
3.2. DrugSemantics Annotation Scheme
The objective of DrugSemantics annotation scheme is
twofold: (a) to identify NEs relevant for pharmacother-
apeutic care that allows dening the annotation guide-
lines; and (b) to annotate SPCs semantically with NEs
from the ones previously identied. Our model is based
on (i) OntoFIS pharmacotherapeutical ontology [48]; and
(ii) common questions about medicines for both healthcare
providers [3, 19] and patients [49]. Using these researches
as a basis, DrugSemantics is able to capture real informa-
tion needs of all the actors involved in the pharmacother-
apeutic process.
Our model contains 10 dierent types of NEs (see Ta-
ble 2): Chemical Composition, Disease, Drug, Excipient,
Food, Medicament, Pharmaceutical Form, Route, Ther-
apeutic Action and Unit of Measurement. Examples for
each NE can be found in Table 3. These entities, together
with their attributes, are described below in alphabetical
order:
Chemical Composition is related to chemical group,
which represents the third level of Anatomical Ther-
apeutic Chemical (ATC) classication9 [51];
Disease relates to any clinical condition and, optionally,
distinguishes between:
 Therapeutic Indication states whether a
medicine must be used for a target disease as
treatment, diagnosis, or prevention (primary or
secondary);
 Interaction, when a set of substances are given
to a patient, some actions can change producing
new clinical conditions and it can be synergistic
(when the drug's eect is increased) or antago-
nistic (when the drug's eect is decreased);
 Contraindication species clinical conditions
when a medication should not be used due to
an allergic reaction, a medical problem, some
physiological change (e.g. pregnancy) or other
treatments/therapies;
 Desirable Eect identies the usages of a medica-
ment to prevent, cure or palliate clinical condi-
tions or a health problem;
 Side Eect refers to unexpected clinical manifes-
tations appearance when a medication is given
on its usual dosage; and
 Overdosage relates to unexpected clinical mani-
festations appearance when a higher dosage than
usual of a medication is given.
Drug is an active substance, which is the designation for
the most specic level of ATC [51]. It distinguishes
9The ATC classication system is widely used internationally and,
in 2003, it was also adapted to be used in the Spanish healthcare
system [50].
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Table 2: DrugSemantics Scheme Named Entities and attributes: Named Entities ordered alphabetically
Named Entity Attributes (=fpredened valuesg)
Chemical Composition type = fchemical group ATC, chemical group ATC code, Chemical Name, Formulag
Disease type = fTherapeutic Indication, Interaction, Contraindication, Desirable Eect, Side Eect,
Overdosageg
Drug type = fDrug Name, Drug ATC Code g
Strength
UnitOfMeasure
Excipient
Food type = fSolid, liquid, Supplements, Additivesg
Medicament TradeName
Country = fSpain, Othersg
Strength
UnitOfMeasure
Pharmaceutical Form
Pharmaceutical Form
Route
Therapeutic Action type = fTherapeuticGroupName, TherapeuticGroupATCCode,
DrugNameGroup, DrugGroupATCCodeg
Unit of Measurement amount
unitname
magnitude
Table 3: Examples from DrugSemantics Scheme: Named Entities ordered alphabetically
Named Entity Example in Spanish (English translation)
Chemical Composition brato (brate)
Disease insuciencia renal (renal failure)
Drug Atorvastatina (Atorvastatin)
Excipient maltosa (maltose)
Food zumo de pomelo (grapefruit juice)
Medicament ALCOSIN 10 mg comprimidos recubiertos con pelcula (ALCOSIN 10 mg lm-coated tablets)
Pharmaceutical Form comprimidos (tablets)
Route oral (oral)
Therapeutic Action analgesicos y antipireticos (analgesic and antipyretic)
Unit of Measurement 10 mg al da (10 mg daily)
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between name or code of an active substance, and op-
tionally, includes strength and unit of measurement;
Excipient is a substance included in medicines for the
purpose of giving shape, consistency, stability, colour,
smell, taste or ease its usage. They can sometimes
be the cause of allergic reactions or other undesired
eects;
Food refers to food taken by patients that can interact
increasing or decreasing the eect of a medicament.
It distinguishes between solid, liquid, supplement and
food additive;
Medicament is constituted by its brand name and,
optionally, by its strength, unit of measurement
and pharmaceutical form; all of which is equiva-
lent to the Spanish designation for commercialised
medicines [40];
Pharmaceutical Form is the possible dosage form in
which these substances are marketed;
Route is a method by which a substance is taken into the
body;
Therapeutic Action \is the means by which a product
achieves an intended therapeutic eect"[52] and it cor-
responds to an intermediate ATC [51] level. Option-
ally, it distinguish between name or code of the ther-
apeutic group, as well as name or code of the phar-
macological group;
Unit of Measurement identies name and quantity of
a magnitude adopted by convention.
3.3. Study Sample and Manual Annotation Process
Annotators received the same 5 SPCs (one for each drug
- see Table 4) to perform the semantic annotation task.
These were randomly chosen from the 30 SPC downloaded
from CIMA (see Section 3.1). The reasons behind giving
complete SPCs were: (i) ease the annotation process and
(ii) facilitate control over the information source.
Table 4: DrugSemantics gold standard characterisation (sample)
Drug S* T** T/S*** NE+
Aspirin 123 3,196 25.98 359
Acetaminophen 146 4,172 28.57 412
Ibuprofen 48 1,225 25.52 81
Atorvastatin 261 8,066 30.9 774
Simvastatin 202 6,040 29.90 615
Total 780 22,679 29.08 2,241
Note: (*) Number of Sentences in each annotated SPC;
(**) Number of Tokens in each annotated SPC;
(***) Average Tokens per sentences in each SPC;
(+) Number of Named Entities per annotated SPC
Annotators were a registered nurse (RN) and two stu-
dents in their nal year from the Degree in Nursing, whose
native language was Spanish. These 3 healthcare providers
(A1, A2, A3) were chosen as annotators due to their phar-
maceutical knowledge and their complete understanding
of Spanish SPCs.
The annotation process lasted approximately three
months, on a part-time basis, and started with an initial
joint training session. Both the annotation tool to use,
GATE Developer [53], and the annotation task, with par-
ticular emphasis on positive examples for each entity and
its attributes, were introduced during this initial meeting.
Once this session nished, each annotator, separately, re-
ceived: (i) 5 SPCs, (ii) the annotation guidelines, with pos-
itive examples, and (iii) an ATC classication listing [54] in
order to help identifying NEs from our annotation scheme.
Each annotator worked independently, meaning that there
was no contact between them while the annotation process
lasted, owing to schedule diculties. This fact ensured
that there was no inuence on the decisions adopted by
annotators, and it is based on the methodology of exper-
imental designs in healthcare, whose purpose is to con-
trol interpretative bias or performance bias [55]. After
the training phase, SPCs annotation was performed in
three steps. First, annotators carried out an initial an-
notation round. Then, each annotator participated in a
9
  
tailor made session to solve doubts and problems that had
appeared during the initial round. Last, a nal annota-
tion round was carried out by each annotator. Its purpose
was that annotators introduce directions given in the pre-
vious step. In this manner, each annotator checked her
labelling through all her documents before delivering the
nal version of her 5 annotated SPCs.
3.4. Metrics for Manual Annotation Evaluation
Once the manual annotation process is completed, its
quality is determined by a set of quantitative metrics. Re-
liability and precision are the two main factors on which
annotation quality depends. Reliability is usually deter-
mined by means of the agreement reached between anno-
tators who worked on the same set of documents [56, 57].
Whereas precision is based on assessing whether a seman-
tic category manually assigned corresponds with a concept
from the annotation scheme [58]. Precision is commonly
assumed if there is agreement. This strategy has been
employed because there is no gold standard that clearly
species what is or not valid, since the reference dataset
is being built [58]. This work does not consider preci-
sion is given by reliability, and as a result, this section
denes metrics to determine DrugSemantics corpus qual-
ity, gauging both reliability and precision at NE category
level (ignoring properties dened DrugSemantics scheme).
3.4.1. Reliability
Reliability of an annotated corpus is computed as the
agreement among independent annotators [56, 57]. Al-
though Kappa coecient has been applied before for mea-
suring agreement over NEs annotation [24, 59], in our case
is not applicable because this coecient takes into account
the probability of agreement by chance [57]. Given that
annotators could label any textual fragment and assign a
category to it, the number of fragments not being consid-
ered a NE is a large number, since these can overlap as
well as vary in length. Consequently, the probability of
agreeing by chance would be near to zero. In these cases,
F-measure (F) is commonly used [22, 26, 37] to estimate
agreement between ratters, since it approaches Kappa [57].
Thus, agreement was calculated for each entity and anno-
tator as a pairwise F-measure between annotators (FA1-
A2, FA1-A3, FA2-A3), and then the average among all
pairs [57]. The following considerations were made:
a) Agreement is calculated as lenient F to allow partial
matches when two annotated NE share a common span
of text [53]. A lenient criterion was chosen due to two
reasons. On the one hand, encoding issues added ex-
tra space characters in our corpus (e.g. an space was
added when an annotation precedes a punctuation sym-
bol). On the other hand, two annotators marked the
same fragment except for few characters, which usually
represented punctuation or a plural ending. For exam-
ple, A1 marked: \malformaciones" (malformations in
English'); whereas A2 tagged: \ malformaciones" in-
cluding the space before the NE begins.
b) F is macro and micro averaged at sentence level.
Macro-averaged F (MF) is calculated across NEs
separately and then the arithmetic mean is com-
puted. Specically for macro-average per annota-
tor pair (Ai   Aj), F is calculated for all sen-
tences (s) and for each entity (e), e.g. for Drug:
fMFAi Aj (Drug; s1); :::;MFAi Aj (Drug; s780)g.
Then, the arithmetic mean of these sentence results per
annotator pair is calculated:
MFAi Aj (Drug) =
P780
s=1 FAi Aj (Drug; s)
780
(1)
Latter, the arithmetic mean of all entities is computed
for each pair:
MFAi Aj =
P10
e=1MFAi Aj (e)
10
(2)
Finally, the arithmetic mean of our three pairs is per-
formed to obtain overall results:
MF =
MFA1 A2 +MFA1 A3 +MFA2 A3
3
(3)
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Whereas micro-averaged F (mF) is calculated ag-
gregating exact matches10, partial matches11 and non-
matches12 counts on the entire corpus before comput-
ing F. Specically for micro-average per annotator pair
(Ai   Aj), sum of counts to obtain cumulative exact
matches (em), partial matches (pm) and non-matches
(nm) are computed for all sentences (s) and for each
entity (e). For example, for Drug exact matches:
emAi Aj (Drug) =
780X
s=1
emAi Aj (Drug; s) (4)
Then, the mF applies traditional F1 formula using
these cumulative sentence results per annotator pair
and entity as follows:
mFAi Aj =
10X
e=1
2(emAi Aj (e) + pmAi Aj (e))
2(emAi Aj (e) + pmAi Aj (e)) + nmAi Aj (e)
(5)
Finally, the arithmetic mean of our three pairs is per-
formed to obtain overall results:
mF =
mFA1 A2 +mFA1 A3 +mFA2 A3
3
(6)
c) Taking into account the lack of consensus on how to
interpret agreement values [56], this work adapted the
Landis and Koch scale [60] for Kappa: F 2 [100; 80]
signies almost perfect agreement; F 2 (80; 60] means
substantial agreement; F 2 (60; 40] represents moder-
ate agreement; F 2 (40; 20] signies fair agreement;
and F 2 (20; 0] means slight agreement.
d) In our opinion, a corpus is reliable when its agreement
exceeds 60 (i.e. F > 60%). Consequently, our hy-
pothesis is that agreement (overall and per annotator
pairs) in DrugSemantics corpus must have a F-measure
greater than 60.
10Two manually tagged NEs share the same type and have exact
character osets (span).
11Two manually tagged NEs share the same type and have a com-
mon span.
12Two manually tagged NEs do not share type nor osets.
e) F is accompanied by a Condence Interval (CI) or a
Maximum Margin of Error13 (MME) to provide a more
detailed reliability description. CIs give more informa-
tion indicating a range of values (interval) that is likely
to contain the true value, with a probability or con-
dence level. In our case, 95% CI has been set and
a signicance level of  = :05. In order to verify our
agreement hypothesis14, when the provided F-measure
is greater than 60, one proportion Z  test=:05 will be
provided. In this case, if such Z value is greater than
Z = 1:645, then the agreement truly exceeds 60% with
signicance level of  = :05.
3.4.2. Precision
Precision measures the consistency of the manual anno-
tation focusing on whether the semantic category assigned
is correct, that is, it corresponds with an appropriate con-
cept from the scheme [58]. In our case, correct (or valid)
denotes whether the manual NE annotation is commonly
used to refer to the selected entity type 15. In this narrow
domain, there is a wide range of knowledge resources that
capture common terms for specic concepts. Thus, preci-
sion for each NE and annotator is estimated as the percent-
age of entities manually annotated by an annotator that
are present in a knowledge resource (e.g. a dictionary)16.
Precision is computed as follows:
Pa(NE;D) =
matcha(NE;D)
totala(NE)
(7)
where a is the annotator's identier; NE is the target
named entity from DrugSemantics scheme; D is a knowl-
edge resource, like a dictionary, that can be employed
for comparison because it includes common terminology
13A Maximum Margin of Error is dened as half of the width of a
CI.
14See item d above.
15For instance, whether acetaminophen is manually annotated as
Drug and it is commonly used to refer to active substances.
16Further details about knowledge resources that are used in this
work can be found in Section 3.5.2
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for a given NE type; totala(NE) is the number of anno-
tations that annotator a has included of type NE; and
matcha(NE;D) is the number of manual annotations of
type NE from annotator a that are present in the resource
D. Specically, the match function compares each anno-
tation of type NE from annotator a with all entries in a
resource D and employs simple string pattern matching
ignoring: accent marks, lower and upper-case letters.
First, precision is being calculated for each entity and
annotator following Equation 7. The purpose is to aid
in the construction of the gold standard: when disagree-
ments between annotators appear, precision will take a
judge role. Then, in order to estimate an overall precision
for DrugSemantics, results were macro and micro averaged
for all annotators.
Bearing in mind that the health domain requires high-
quality NLP resources to avoid errors and its consequences,
our hypothesis is that precision in DrugSemantics must
have a Precision greater than 80%. Precision is accompa-
nied by CI or MME to provide a more detailed description.
Likewise F, 95 % CI and signicance level of  = :05 has
been set. Similarly, one proportion Z   test=:05 is pro-
vided to verify our hypothesis when Precision is greater
than 80.
3.5. Methodology for Manual Annotation Evaluation
This section describes the procedures followed to as-
sess manual annotation for each semantic category within
DrugSemantics scheme. First, Section 3.5.1 outlines
the method to compute Reliability applying F (see Sec-
tion 3.4.1). Last, Section 3.5.2 denes the method to apply
Precision (see Section 3.4.2).
3.5.1. Reliability
Once the annotation process nished, agreement be-
tween annotators was calculated with Corpus Quality As-
surance, from GATE Developer [53]. Before, an initial
preprocessing was conducted to detect sentences within
our study sample (5 SPCs manually annotated by 3 an-
notators). To that end: i) points were added at the end
of a title in every section (rst level heading) and, if nec-
essary, in every subsection (second level heading) aiming
at facilitating the identication of sentences; ii) manual
annotations on titles were deleted; iii) both headers and
footers, in each labelled SPC, were removed; and nally
iv) sentences were automatically detected by LingPipe, a
GATE Developer [53] plugging.
3.5.2. Precision
Annotation precision was calculated semi-automatically
to compute precision between manual annotations and
DrugSemantics annotations scheme. This method used an
existing dictionary-based NER system, MaNER [61, 62],
in order to reduce the expense of the manual review pro-
cess for correctness. Each entity MaNER recognises has its
own dictionary. Each dictionary was gathered from a reli-
able biomedical knowledge resource and it contains a list
of terms representing common and relevant vocabulary for
a given NE [63]. The purpose of using a NER system was
to manually review only those annotations that are not
present in the dictionaries. However a high eort was still
required to manually examine these annotations. Thus, it
was decided to review by hand all entities from DrugSe-
mantics scheme except from Disease, given that each Dis-
ease subtype required a dierent dictionary to decide if an
annotation is correctly tagged.
Initially, MaNER [61, 62] recognized four NE (i.e.
Medicament, Drug, Pharmaceutical Form and Route).
Hence, such system was extended to include the ve miss-
ing entities (i.e. Chemical Composition, Excipient, Food,
Therapeutic Action and Unit of Measurement). Besides,
a new dictionary for Drug was created to replace Ac-
tiLex dictionary [61, 62] and overcome issues previously
reported [62], such as multi-words inversion. Therefore, 6
new Spanish dictionaries were created and 3 were kept. All
of them were acquired by querying several reliable biomed-
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ical knowledge resources, namely:
Chemical Composition: its dictionary was built from
ATC [51].
Drug: its dictionary was obtained from ATC [51], which
replaced the original MaNER dictionary for this en-
tity, ActiLex [61, 62].
Excipient: its dictionary was gathered from the Interna-
tional Numbering System for Food Additives [64].
Food: its dictionary was compiled from BEDCA [65].
Medicament: MePLex dictionary [61, 62] was built from
Nomenclator Digitalis [66].
Pharmaceutical Form: its dictionary [61] was obtained
from Nomenclator Digitalis [66].
Route: its dictionary [61] was obtained from Nomencla-
tor Digitalis [66].
Therapeutic Action: its dictionary was gathered from
ATC [51].
Unit of Measurement: its dictionary [61] was compiled
from SNOMED-CT [67].
Precision was estimated in four stages, as follows:
1. Comparison: Text fragments manually annotated
were compared automatically against its dictionary
with exact matching, meaning that our comparison
employed simple string pattern matching between to-
kens ignoring only accent marks and capitalization.
As a result, a list of not matched annotations was
generated automatically for each DrugSemantics en-
tity included in this experiment.
2. Analysis: These lists were manually analysed to know
how to update our dictionaries. Each annotation not
matched was classied as dictionary fault, human er-
ror17 or partial match (i.e. a manual annotation rep-
17Errors in manual annotations, e.g.: physiology of administration
routes (\ingestion" - intake) instead of the route itself (\oral").
resents an entry in the dictionary, but the former in-
cludes the omission or addition of a character, such
as a punctuation symbols).
3. Update: As a result, dictionaries were updated with
the annotations classied as dictionary fault to per-
form an exact perfect matching. In this manner, the
dictionaries were enhanced to detect more valid an-
notations. Additionally, manual annotations labelled
as a partial match were xed by means of adding or
removing missing characters.
4. Precision: Again, annotations were compared au-
tomatically and precision was calculated for each
DrugSemantics entity included within this experi-
ment.
3.6. Gold Standard Construction
Once the evaluation nishes, a gold-standard is built. In
our case, the nal corpus was created by combining anno-
tations from our three annotators to obtain the largest set
of annotations of the highest quality possible in terms of
precision. To that end, agreements between at least two of
three annotators became part of the DrugSemantics cor-
pus, if FAiAj (NE) is greater than 60%. It should be noted
that Disease entity agreements were strict (character o-
sets) and considered its type (e.g. Overdosage, etc.) to
decide whether an annotation was in our nal corpus or
not.
Discrepancies were solved using MaNER dictionaries as
a judge, if available: when only one annotator a detects an
entity ne1, this annotation would be included in the gold
standard, if it matches its dictionary D and its precision
Pa(NE;D) exceeds 80%. This approach would be applied
also when FAiAj (NE) is less than 60%, but Pa(NE;D)
exceeds 80%.
Besides, when two annotators detect the same entity
but its scope diers (i.e. inexact character osets dis-
agreements), the chosen annotation was the one that is
more faithful to the DrugSemantics Scheme or more spe-
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cic, even though this annotation is not the most frequent.
For instance, it was preferred mentions of Drugs that con-
tained their strength (amount and unit of measurement)
in the original text, regardless the number of annotators:
\20 mg de simvastatina" (20 mg of Simvastatin) instead
of \simvastatina" (Simvastatin). Regarding annotation
specicity, MaNER dictionaries were employed to decide
in this case. For example, \Soluciones Orales" (oral solu-
tions) appear in text and only one annotator included it as
Pharmaceutical Form but the others only selected \Solu-
ciones" (solutions), the rst one was chosen because it's
more specic.
3.7. Gold Standard Use Case: Named Entity Classica-
tion
In order to show how this corpus cold be used, this sec-
tion presents a pilot use case. The DrugSemantics corpus
is designed to be used in the Named Entity Recognition
and Classication (NERC) task. The goal of NERC is to
recognize occurrences of NEs in text, which is known as
the recognition phase (NER), and assign them a category,
which is referred as the classication phase (NEC). Since
NERC can implement both phases separately, our use case
is focused on the latter (NEC) assuming the output of a
\perfect" NER so as to avoid any bias. Specically, we em-
ployed the NEC from [68{70], which is based on Machine
Learning (ML) and proles. A more detailed description
of our method can be found in [69].
This NEC uses the DrugSemantics gold standard as
training corpus, whereas the SpanishADR [37] corpus is
employed for testing purposes. Although these corpora
used dierent annotation schema and entities are not an
exact match, some entities are closely related. For in-
stance, our Disease entity is a generalization of Adverse-
Eect entity from SpanishADR. Therefore, this use case
is applied to the most frequent entities from both data
sets: 724 Disease (DrugSemantics) versus 545 AdverseEf-
fect (SpanishADR).
The performance of this NEC was assessed in terms of
traditional Precision (P), Recall (R) and F  measure=1
(F1) for the positive class (i.e. is Disease or is AdverseEf-
fect).
4. Results
4.1. Reliability Results
Table 5 presents DrugSemantics corpus reliability, com-
puted for each annotator pair and globally in terms of Le-
nient F-measure, its MME and its Z-value. These values
are based on 95% CI and 0.05 signicance level.
The results in Table 5 by pair show that when annotat-
ing most entities (6 out 10) agreement is truly substantial
(5) or almost perfect (1) for all pairs. A noteworthy agree-
ment is reached by the student pair (A1-A2), in which 9
out of 10 entities conrm our hypothesis are truly substan-
tial (i.e. F values are truly above 60).
Overall agreement between all pairs, considering both
macro (F 72.33% [95%CI: 71.25-73.41]) and micro average
(F 79.33% [95%CI: 78.35-80.31]), were substantial between
annotators (F 2 (80; 60]). But the latter is very close to
the upper limit of this range. Looking closer, the majority
of them (8 out of 10) exhibits substantial or almost per-
fect agreement, that is, most obtained an F higher than
60. Only two of them have a lower agreement: Chemical
Composition - F 2 (60; 40] - and Therapeutic Action -
F 2 (20; 0].
Thus, reliability of DrugSemantics manual annotation is
satisfactory.
4.2. Precision Results
Annotation Precision between manual annotations and
DrugSemantics annotation scheme is presented in Table 6,
as well as its MME and its Z-value. These values are based
on 95% CI and 0.05 signicance level.
Overall precision among annotators, considering both
macro (90.05% [95%CI: 89.33-90.77]) and micro (94.74%
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Table 5: Named Entity agreement (Lenient F-measure with its Maximum Margin of Error and Z-value) in DrugSemantics corpus per entity
and globally, ordered by global agreement
Named Entity FA1 A2 MME Z FA1 A3 MME Z FA2 A3 MME Z FMME Z
Medicament 100 93  5.93 10.9 93  5.93 10.9 95.33  3.98 17.4
Excipient 94  4.18 15.94 95  3.84 17.88 88  2.99 9.35 92.33  3.86 16.43
Unit Of Measurement 89  1.91 29.69 89  1.89 30 90  1.81 32.53 89.33  1.60 32.31
Drug 98  0.76 97.37 80  2.32 16.89 81  2.29 17.96 86.33  1.60 32.53
Pharmaceutical Form 83  7.33 6.15 88  6.22 8.83 82  7.94 5.43 84.33  5.86 8.14
Food 96  5.66 36 71  12.84 1.68 70  13.24 1:48
 79  9.54 3.94
Disease 82  1.85 23.30 65  2.45 4 69  2.48 7.11 72  1.87 12.60
Route 85  7.22 6.79 57  10.78 # 62  11.29 0:35
 68  8.24 1.90
Chemical Composition 73  6.56 3.88 37  6.25 # 30  6.24 # 46.67  5.59 #
Therapeutic Action 14  12.85 # 4  5.23 # 12  7.72 # 10  6.79 #
Macro-average 81  1.13 36.35 68  1.39 11.32 68  1.41 11.10 72.33  1.08 22.36
Micro-average 88  0.94 58.52 74  1.3 21.06 76  1.29 24.25 79.33  0.98 38.72
A1: Annotator 1, student; A2: Annotator 2, student; A3: Annotator 3, nurse; MME: Maximum Margin Error; Z: one proportion Z-test value;
#: F-measure below our hypothesis; Z column bold-faced: agreement truly has an F>60% with a 95% condence; 
: There is a lack of
evidence to reject our null hypothesis (F=60%) and to accept our hypothesis (F>60%).
Table 6: Annotation Precision between DrugSemantics scheme and the following Named Entities: Medicament, Drug, Unit of Measurement,
Route, Therapeutic Action, Pharmaceutical Form, Excipient, Chemical Composition and Food. Ordered as in Table 5.
Named Entity PA1 MME Z PA2 MME Z PA3 MME Z
Medicament 100 100 97.06  5.68 5.89
Excipient 100 100 100
Unit Of Measurement 100 99.03  0.84 44.19 99.07  0.83 45.22
Drug 99.39  0.60 63.54 99.21  0.69 54.72 95.92  1.75 17.81
Pharmaceutical Form 100 100 93.62  6.99 3.82
Food 100 100 100
Route 82.69  10.28 0.51
 85.71  10.58 1.06
 79.31  14.74 #
Chemical Composition 66.67  9.29 # 81.82  9.84 0.36
 30  7.88 #
Therapeutic Action 85.71  25.93 0.81
 100 36.17  13.74 #
Overall Macro-average (A1+A2+A3)  MME Z 90.05  0.72 27.24
Overall Micro-average (A1+A2+A3)  MME Z 94.65  0.54 52.81
A1: Annotator 1, student; A2: Annotator 2, student; A3: Annotator 3, nurse; MME: Maximum Margin Error;
Z: one proportion Z-test value #: Precision below our hypothesis; Z column bold-faced: agreement truly
has a P>80% with a 95% condence; 
: There is a lack of evidence to reject our null hypothesis (P=80%)
and to accept our hypothesis (P>80%).
[95%CI: 94.11-95.19]) was almost perfect. Dierences be-
tween macro and micro-averaging are due to the fact
that macro treats all classes equally, while micro-averaging
favours bigger categories (such as Drug and Unit of Mea-
surement). Taking into account precision for each annota-
tor:
Annotator 1 obtains a precision lower than 80% for
Chemical Composition. Although Route and Thera-
peutic Action have a precision above this value, its Z-
value tell us that our hypothesis can not be accepted.
The six remaining ones are truly above this cut-o
point.
Annotator 2 gets a precision higher than 80% for all
NEs. However, there is no evidence that conrms that
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Route and Chemical Composition are truly below this
cut-o point.
Annotator 3 obtains a precision lower than 80% for
Chemical Composition, Therapeutic Action and
Route, whereas the remaining ones are above this cut-
o point.
Thus, precision results indicates that manual annotation
worked remarkably well for almost all entities and annota-
tors (except Chemical Composition, Route and Therapeu-
tic Action). As a consequence, precision of DrugSemantics
manual annotation is adequate.
4.3. Gold Standard Distribution
Finally, our gold standard is built according to the rules
specied in Section 3.6. As a result, the frequency for each
entity type can be seen in Table 7 - column GS. Besides,
details about manual annotations per entity and annota-
tor are also provided (columns A1-A3) to show dierences
between annotators and the nal corpus. In the gold stan-
dard, specically, Disease and Drug entities are the most
numerous ones. On the contrary, the more uncommon gold
standard NE, with a frequency less than 30, is Therapeu-
tic Action. Gold standard distribution is generally main-
tained by all annotators across entities, but A3 is the one
that introduces more changes (e.g. Drug or Therapeutic
Action).
Our gold standard is publicly available for research pur-
poses (more information in [71]).
4.4. Gold Standard Use Case Results
Table 8 presents results when a NEC system is trained
to classify the Diasese Entity (from DrugSemantics gold
standard) versus the AdverseEect (from SpanishADR
corpus). It should be noted that training and testing
sets are composed of dierent textual genres. On the one
hand, SPCs are formal, longer and normalized documents.
Table 7: Statistics about DrugSemantics corpus
Named Entity
Annotations
GS A1 A2 A3
Disease 724 887 769 567
Drug 657 651 636 490
Unit of Measurement 557 508 518 540
Excipient 66 65 59 59
Chemical Composition 62 99 77 130
Pharmaceutical Form 45 58 43 47
Route 42 52 42 29
Medicament 37 37 37 34
Food 31 24 22 24
Therapeutic Action 20 7 21 47
Total 2,241 2,388 2,224 1,967
GS: gold standard; A1: Annotator 1, student;
A2: Annotator 2, student; A3: Annotator 3, nurse.
On the other hand, text in forum comments are infor-
mal, smaller and content free. Besides, dierent annota-
tion schema are employed.
Despite these facts, Precision (Pr), Recall (Re) and F1
are always higher than 70% and less 80%. As a conse-
quence, these results prove that DrugSemantics gold stan-
dard is useful to deal with named entities, even if the tex-
tual genre changes.
Table 8: Example Use Case results: Named Entity Classication
NE Training NE Test Pr Re F1
Disease AdverseEect 78,8 70,1 74,2
Note: Pr: Precision; Re: Recall; F1: F  measure=1;
NE Training: entity from DrugSemantics corpus
as training; and NE Test: entity from SpanishADR
corpus for testing.
5. Discussion
This section analyses our obtained results and those are
compared with previous research. This section is divided
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in ve parts. First, Section 5.1 examines the methodol-
ogy employed for the annotation of DrugSemantics cor-
pus. Next, Section 5.2 analyses the methodology applied
to asses the quality of DrugSemantics gold standard. Lat-
ter, Section 5.3 emphasizes DrugSemantics reliability re-
sults. This is complemented by a comparison between our
reliability results and the ones from other relevant research
(Section 5.4). Finally, DrugSemantics precision is high-
lighted (Section 5.5).
5.1. DrugSemantics annotation methodology
From a critical perspective, several factors may have af-
fected the DrugSemantics gold standard due to the anno-
tation methodology carried out. The rst one is related
to the knowledge annotators should have on the working
domain. A high quality standard annotation is typically
expert-driven [20{27, 37] to ensure consistently great qual-
ity corpora. However, researchers have shown that non-
expert annotators can be as good as experts with appro-
priate training [72, 73]. In our case, annotators had a pri-
ori an adequate level of pharmacotherapeutic knowledge
(1 RN and 2 students in their nal year from the Degree
in Nursing). However, this knowledge varies over time and
it seems more consolidated during university than during
professional practice, as our results shown (cf. Tables 5-
6). In Spain, once the title of RN is obtained, there is
no certication to update knowledge periodically, which
may be aected by the type of employment carried out.
Such limitation was not considered during the annotators
selection process and might explain the observed discrep-
ancies. It should be remember that annotator RN obtains
the worst results in comparison with students. Specically,
this inuence are evinced by our precision analysis. For in-
stance, Therapeutic Action entity is the one that has more
detected errors, either this EN is ignored or it is confused
with other substances (Drug or Chemical Composition).
However, a combination of dierent perspectives (i.e. two
students and one professional) has been considered ade-
quate to ensure that the annotation represents better the
entities under investigation.
The second one is related to the number of annotators
involved in the process, which varies depending on the
available resources: 2 [20, 24, 37], 3-5 [21, 23], > 6 an-
notators [22]. Although there is no standard number of
annotators, there is a consensus to annotate documents
by at least two annotators independently. During train-
ing, disagreements are usually solved with all annotators
present in order to achieve an agreement and update the
guidelines accordingly. In order to build the gold standard,
dierences are traditionally resolved by an experienced an-
notator (i.e. a judge) or by consensus between annotators.
Besides, the number of annotators not only inuences the
eort required to assure corpus quality, but also the re-
sulting size (i.e. more pairs produce larger corpora). In
light of these, two alternative methodologies have emerged
lately trying to overcome these limitations: crowdsourcing
and translation. Both are cheaper and faster than tradi-
tional annotation eorts, but these are not exempt from
certain drawbacks.
Crowdsourcing18 is a collaborative approach for obtain-
ing larger annotated corpora that allows annotators to
work independently no matter the distance. Notwith-
standing certain researchers have used the crowd to an-
notate in the healtcare eld, such as [74, 75], \a remain-
ing challenge is that the cost to dene a single annota-
tion crowdsourcing project can outweigh the benets" [76].
Furthermore, \there are legitimate concerns that could be
raised regarding its use for medical research" [74].
Another option to obtain an annotated corpus would
consists in translating automatically existing pharma-
cotherapuetic corpora. Although it would be possible, the
outcome could be inaccurate for various reasons, which
are typical of this challenging domain. Most drugs have
names that could be translated using the ATC classica-
18For instance, paid-for marketplaces such as Amazon Mechanical
Turk or CrowdFlower.
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tion system. However, all countries do not accept specic
substances in their healthcare systems. Besides, a phar-
maceutical company may commercialize a medicine using
dierent names or using a other set of active substances
depending on the target country. Hence, it is not possi-
ble to transfer all substances between healthcare systems.
More problems of machine translation in the medical do-
main can be found in [77].
Bearing in mind all these standard practices, DrugSe-
mantics annotation methodology was designed by using
high level annotation standards with certain adaptations
to satisfy the needs and peculiarities of our research frame-
work. Instead of solving training disagreements with all
annotators, DrugSemantics provided a tailor made session
to solve doubts guided by one of the authors (MT R-F).
The reason was to avoid annotators decision' bias (i.e.
annotators could inuence each other in a joint session),
which in turn would have aected precision results. Re-
garding DrugSemantics gold standard building, two strate-
gies were applied. First, common consensus through ma-
jority voting was utilized. Second, disagreements, in-
stead of being discarded, were resolved. To that end, the
judge annotator was a semi-automatic process driven by a
named entity recognition and classication system based
on knowledge [61, 62]. In this manner, DrugSemantics an-
notation methodology ensured manual annotations of the
highest quality, which in turn drove our rigorous gold stan-
dard construction process.
5.2. DrugSemantics quality evaluation methodology
Similarly, several aspects may have an eect upon
DrugSemantics evaluation. Regarding reliability, at-
tributes of each entity, as well as condence of the anno-
tator, were not taken into account when computing agree-
ment. Properties were included in DrugSemantics scheme
to give hints to annotators; this made the entity identica-
tion more eective. In fact, ll the attributes of each entity
is a dierent information extraction task (e.g. association
of a given drug to its strength [27]), which is beyond the
scope of this work.
Concerning precision, it is important to emphasize that
our pipeline is general enough to be applied in other an-
notated corpora with NEs. To that end, MaNER [61, 62]
can be changed for a dictionary-based NE recognition and
classication tool. Besides, knowledge resources can also
be changed or updated provided that these are carefully
selected due to their informative and reliable value. As
previously stated, since there is a lack of Spanish resources
in this domain, a careful analysis was made. For instance,
BEDCA [65], a Spanish database containing terms related
to food that do not follow the terminology of SPCs, or
Food Additives [64], is a resource that contains a small
number of excipients. Both resources were the only ones
we found related to these entities, but they needed an
update process to represent more accurately language of
SPCs. Discarding these entities from precision analysis
was not an option owing to their importance for detecting
interactions and allergic reactions. On the contrary, larger
knowledge sources were identied: (i) SNOMED is an on-
tology that is the de facto standard for semantic interop-
erability available for Spanish; and (ii) ATC and Nomen-
clator digitalis are the common reference source in Spain.
Furthermore, our precision methodology could be applied
to all NLP tasks that can be resolved with dictionary-
based approaches. It is important that those dictionar-
ies are populated with informative and reliable knowledge
resources, provided that these include terminology com-
monly used in the textual genre selected for the resulting
corpus [63].
5.3. DrugSemantics Reliability
As we have seen in Section 4.1, the DrugSemantics cor-
pus has evaluated its reliability in terms of agreement as
lenient F-measure. Overall agreement, both micro (79.33
95%CI [78.35-80.31]) and macro (72.33 95%CI [71.25-
73.41]), are substantial, since their lower limit CI is greater
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than 60. Besides, our hypothesis is conrmed for all pairs
at an overall level (see Table 5). As a result, the man-
ual annotation was reliable. Besides, dierences between
these averages are due to the unbalanced NEs distribution
(they do not have a similar number of entities).
Looking at the results per NE, Medicament, Excipient,
Unit Of Measurement, Drug and Pharmaceutical Form
had almost perfect agreement (F 2 [80; 100] - see Table 5).
That leads us to interpret that these entities are easier to
annotate. Despite the fact that Disease is the most com-
mon entity and the one with a higher variability in terms of
occurrences (A1=887, A3=567), it was harder to annotate
since it only achieved substantial agreement (F 2 (80; 60]).
This may be due to dierent disease designations according
to the role of a medicament and its drugs (e.g. Therapeu-
tic Indication, Contraindication, Overdosage, Side Eect).
Although they received clear instructions in this regard,
make that dierence was dicult for annotators. Food
and Route entities also have substantial agreement in ab-
solute terms. However, not all annotator pairs conrm
our hypothesis for these two entities: A2-A3 pair (Food
and Route), and A1-A3 pair (Route). Other reasons be-
hind these variations may be: (i) Disease and Food en-
tities are usually formed by several tokens, for instance,
\insuciencia renal moderada" (moderate kidney failure),
\colorantes azoicos" (azo-dyes); and (ii) Route entity often
corresponds to one token but is preceded by trigger words,
such as \va" (via), that may mislead to incorrect bound-
aries detection. This fact, in addition to the inclusion of
extra spaces and punctuation symbols in the annotations,
motivated our decision of using a lenient criterion in order
to count them at least as partial-matches.
5.4. Reliability Comparison with the State of the Art
Comparing our reliability results with other Spanish re-
search [20, 37] is not free of certain limitations. First,
Ixa-MedGS [20] used a dierent reliability metric (i.e. In-
ter Annotator Agreement, a.k.a. IAA). IAA is computed
in terms of matches and non-matches, which in turn re-
fer to other variables commonly employed to compute F-
measure. On the one hand, matches is also known as True
Positives or correct19. On the other hand, non-matches
refers to errors denoted as False Positive and False Nega-
tive or Type I and Type II. Therefore, although the metrics
have dierent names, IAA and F-measure are calculated
using the same gures and, as a result, both are equiva-
lent, as shown in [23]. Besides, our work, as well as [20],
chose a lenient criterion but nothing is said in SpanishADR
corpus [37]. Hence we could assume [37] chose a strict cri-
terion so as to not take into account partial matches.
Second, despite the fact that these corpora gathered
Spanish health texts, each eort choose distinct types of
documents (Forums comments [37], clinical documents [20]
and SPCs) that do not pose identical challenges. For in-
stance, patients tend to use shorter terms and informal
language. While professionals often employ abbreviations,
short and agrammatical sentences to ll patient health
records. Whereas specic terms, formal language and long
sentences are utilized to avoid ambiguity in SPC for future
references.
Third, entity types across schema are not always a per-
fect match because there is no consensus within medical
NLP community concerning which elements must be con-
sidered. The well-known ones barely scratch the surface of
NEs that would be useful for all text mining purposes [18].
Finally, only three out of ten NEs from DrugSemantics
scheme are present in other Spanish corpora, namely:
Medicament, Drug and Disease.
Consequently, the DrugSemantics corpus complements
the eorts to build NLP resources for the Spanish pharma-
cotherapeutic domain. Therefore, a reliability comparison
between our corpus and Spanish corpora presented in Sec-
tion 2 is provided in Table 9. Such comparison is focused
on two groups of entities that represent both similar con-
cepts.
19Please note that partial matches can also be considered.
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Table 9: Annotated Corpora Reliability Comparison, ordered by DrugSemantics agreement. Only shared entities for Spanish eorts.
Named Entity DrugSemantics Ixa-MedGS SpanishADR
Medicament + Drug F=90.83*[89.53-92.13]$ IIA=92.12 F=89
Disease F=72[70.13-73.87]$ IIA=89.81 F=59
Note: (*) Macro-averaged F-measure between Medicament (F=95.33%) and Drug (F=86.33%); ($) 95% Condence Interval
Table 10: Annotated Corpora Reliability Comparison, ordered by DrugSemantics agreement. Only shared entities for English eorts.
Named Entity DrugSemantics i2b2 DrugDDI CLEF
Medicament F=95.33[91.35-99.31]$ - K=88.53 -
Drug F=86.33[84.73-87.93]$ - K=84.67 -
Medicament + Drug F=90.83[89.53-92.13]$ F>90 - IIA=85
Unit of Measurement F=89.33[87.80-90.86]$ F>61.3 - -
Disease F=72[70.13-73.87]$ 70.5F75.3 - IIA=84
Route F=68[59.76-76.24]$ F>90% - -
Therapeutic Action F=10[3.21-16.79]$ - K=82.99 -
Note: ($) 95% Condence Interval
First, Medicament and Drug entities are combined in
one single type. For this reason, we calculate a macro-
averaged F-measure between our two values (see Table 9
Medicament + Drug). All corpora reported almost perfect
agreement for this group with minor variations. In Ixa-
MedGS case, their results are slightly higher than ours;
whereas SpanishADR F1 is a little less than ours. In
our opinion, these minimum dierences are related with
a combination of two factors. On the one hand, each type
of genre has dierent problems, as noted earlier. On the
other hand, the eort required for the annotation task is
dierent. Ixa-MedGS and SpanishADR have less elements
in their annotation schema than DrugSemantics. Further-
more, Ixa-MedGS pre-annotate their documents, thus the
annotation task is easier than SpanishADR and DrugSe-
mantics annotation.
Second, Disease is present in all eorts but the dier-
ences are more evident. For Ixa-MedGS corpus, Oronoz
et. al [20] reported an agreement higher than ours. These
dierences may be due to the fact that their task was less
complex, since their annotators had to revise automati-
cally annotated entities, remove incorrect ones and add
missed ones. SpanishADR includes a subset of our Dis-
ease (i.e. adverse drug reactions) and exhibit moderate
agreement (F = 59%). Discrepancies in SpanishADR cor-
pus, could be due to a greater variability and richness in
patients comments than SPCs. For instance, patients tend
to use shorter terms and informal language, as said earlier,
and they could write: \infarto" (heart attack) but also
\infart" or \1nfart" or \nfrt", while SPCs would employ
formal texts and longer words to avoid ambiguity, such as
\infarto de miocardio" (myocardial infarction).
We can claim that our reliability is in-line with other
Spanish corpora and sometimes better, despite that: (i)
our annotation scheme includes a higher number of enti-
ties which increases obstacles during manual annotation
(ratters deal simultaneously with ten NEs across 5 doc-
uments with 780 sentences and 22,679 tokens); and (ii)
our annotators were free to label any textual fragment on
a SPC, while Ixa-MedGS used pre-labelled corpus before
annotators intervene.
As regards to English corpora, the reliability among ef-
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forts is not directly comparable due to substantial dier-
ences among these languages. Still, our agreement results
are comparable with what has been shown for other En-
glish corpora, as can be seen in Table 10. DrugSemantics
annotation scheme is more similar to English than Spanish
schema. As in the Spanish case, the documents gathered
to create English corpora (EHR, scientic abstracts, Drug-
Bank texts) are dierent to the one this paper employed
(SPCs), even though DrugBank texts and SPCs are the
most similar ones. Our agreement results are analogous to
other English eorts, since our reliability is almost perfect
and substantial for 6 NEs; despite the weak agreement for
our Therapeutic Action.
Finally, it should be noted that although DrugSeman-
tics may seem limited in terms of size (only 5 SPCs), our
resource present a high level of richness in terms of lin-
guistic and semantic elements. For instance, Ixa-MedGS
is the corpus with the highest number of sentences (almost
73 - see Table 1), tokens (555.11 - see Table 1) and entities
(around 53 ENs - see Table 1) on average per document.
However, DrugSemantics increases all these gures on av-
erage per document: sentences raises 2 times (156 - see
Table 1), tokens raises 8 times (4,535.8 - see Table 1) and
NEs increases 7 times (more than 400 entities - see Ta-
ble 1). Proportionally, DrugSemantics is bigger because
our documents are longer and semantically richer on aver-
age than similar corpora in this domain.
5.5. Precision
Before computing the precision gures, the lists of not
matched annotations for each entity and annotator were
analysed manually in depth. As a result, Table 11 presents
all types of conicts identied initially in all our dictionar-
ies before computing Precision. In view of this analysis,
precision relies heavily on knowledge resources (i.e. dic-
tionaries), as expected. The good results are due to the
manual identication of dictionary issues, which allowed to
ignore false errors. These dependencies were overcome by
adding the required variations (abbreviations, etc.). The
identied types of conicts in all our dictionaries are:
Table 11: Dictionary gaps in relation to Annotation Precision by
entity. Ordered increasingly by number of gaps.
Named Entity Gaps
Medicament 
Food   
Excipient    
Route    
Therapeutic Action    
Unit of Measurement    
Drug     
Pharmaceutical Form     
Chemical Composition      
Note: (): Abbreviation; () White-spaces and hyphens;
() Specic entries; () Lexical variations; () Lack of synonyms;
() Human failure and partial match.
() Abbreviations are excluded : During examination, it
was noticed that Drug, Route, Unit of Measurement
and Chemical Composition dictionaries, only contain
full names. In the case of Unit of Measurement,
\gramos" (grams) is an entry, but \g." (g.), its
acronym, is not. A potential solution would be to
include these acronyms in their relevant dictionaries.
() Special characters are considered : On the one hand,
white spaces and hyphens are considered for some en-
tities that can be named after codes. Such codes are
a single term in our dictionaries. However, Drugs and
Excipients annotations often include hyphens or white
spaces that do no produce an exact match. For exam-
ple, in the case of Excipient NE, \E122" is included in
its dictionary but \E-122" is not. On the other hand,
break-line character as well as adjectives or articles
are considered for names of Drugs, Chemical Compo-
sitions, Pharmaceutical Forms, Excipient and Food.
For instance, in the case of Chemical Composition en-
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tity, \Inhibidores de Proteasa" (Protease Inhibitors)
is an entry in its dictionary but \Inhibidores de la
Proteasa" (Inhibitors of the Protease) is not. Modify
the matching rule to ignore these characters, could be
a possible solution.
() Lexicons contain terms too specic: One of the most
common problem among dierent NEs is related to
dierences in granularity. This happens to Drug, Unit
of Measurement, Route, Pharmaceutical Form, Ther-
apeutic Action, Excipient, Chemical Composition and
Food. This issue is more obvious for Food, since no
matches could be produced when comparing manual
annotations to its original dictionary. For instance,
\Zumo de pomelo, envasado" (grapefruit juice, pack-
aged) belongs to the dictionary but it must be sep-
arated in two: \Zumo de pomelo" (grapefruit juice)
and \Zumo envasado" (packaged juice). Hence, the
terms within our dictionaries should be generalized
to obtain a coarser granularity. This generalization is
not trivial and needs to be carefully planned to ensure
dictionaries reliability. For example, \hipoglucemi-
antes" (hypoglycemics) is a Therapeutic Action, but
this word is included along several entries in Chemi-
cal Composition dictionary. For instance, \Combina-
ciones de drogas hipoglucemiantes orales" (Combina-
tions of oral blood glucose lowering drugs) can not be
divided to provide new terms in Chemical Composi-
tion dictionary.
() Lack of synonyms: Our dictionaries contain a large
amount of entries, however all their synonyms are not
included or most of them are in only one entry. This
is the case of Drug, Therapeutic Action, Excipient
and Food. For example, Excipient dictionary has as
entry \azorrubina, carmoisina" (azorubine, carmoi-
sine), but it must be separated in two: \azorubina"
(azorubine) and \carmoisina" (carmoisine). Hence,
entries with several synonyms, need to be splitted to
be a match and provide a coarser granularity.
() Lexical variations are considered : Some disagree-
ments were due to misspellings, but also to gen-
der and number variations of the following enti-
ties: Drug, Therapeutic Action, Pharmaceutical Form
and Chemical Composition. For instance, Thera-
peutic Action dictionary has as entry \Antiacidos"
(antacids) in plural, but in SPCs its singular form
also appears \antiacido" (antacid). Thus, a possible
solution could be to lemmatize entries in dictionaries,
this way the matching rule could be done at lemma
level, instead of using exact pattern matching.
Despite these dictionaries gaps, we can arm that man-
ual annotation of DrugSemantics is a success globally:
both micro (P = 94:65% [95%CI: 94.11-95.19]) and macro-
average (P = 90:05% [95%CI: 89.33-90.77]) conrm our
hypothesis. Furthermore, it is important to highlight
that agreement measures are the only ones reported for
other annotated corpora. However, this paper proposes a
methodology to provide agreement and precision results,
considering that computation of both measures strengthen
the quality of corpora.
On the one hand, precision at entity level conrms relia-
bility of DrugSemantic corpus. That is, in the vast major-
ity of entities obtained outstanding results for both indi-
cators regardless annotator or pair, specically: Medica-
ment, Excipient, Unit of Measurement, Drug and Phar-
maceutical Form.
On the other hand, dierences between the two sug-
gest that certain entity mentions were wrongly missed by
one annotator of the pair. For example, Therapeutic Ac-
tion obtained the lowest agreement (globally and by pair).
However, A2 got an excellent precision for this entity
(100%), reason why we include these high quality annota-
tions in DrugSemantics. In these cases, therefore, the sta-
tistical hypothesis tests notably assist in the gold-standard
construction process by means of restricting which annota-
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tions have truly enough quality to be included in the nal
set.
As a result, DrugSemantics has a high quality with the
fewest possible errors so as to not bias a NE recognition
and classication algorithm. That is also conrmed by the
results presented in the use case (see Table 8).
6. Conclusions
This paper has presented the DrugSemantics corpus,
a collection of Spanish SPC. These documents have
been manually annotated to include signicant NEs for
the pharmacotherapeutic process, which are specied in
DrugSemantics annotation scheme. To the best of our
knowledge, no corpus of annotated SPCs written in Span-
ish has been created to date. Furthermore, no corpus
in this domain has been annotated with an annotation
scheme as complete as DrugSemantics to date.
Besides, the quality of this corpus has been assessed by
means of measuring annotation reliability (overall agree-
ment, F=79.33% [95%CI: 78.16-80.50]), as well as preci-
sion (overall precision, P = 94:65% [95%CI: 94.11-95.19]).
For the latter, a semi-automatic methodology is proposed,
which is general enough to be applied on other NLP
datasets. To that end, a NE recognition system, which
is dictionary-based, has been developed for 9 out of 10
entities.
Given this substantial agreement, this almost perfect
precision and the statistics hypothesis testing, a high qual-
ity gold-standard has been created. The resulting corpus
contains more than 2,000 named entities spread in 5 SPCs,
780 sentences and 22,659 tokens. Our gold standard is
publicly available for research purposes [71].
A successful example of how to use the DrugSemantics
corpus has been shown, in which a NEC system classies
Disease entity. To that end, the DrugSemantics gold stan-
dard has been employed to train this system. In order to
prove whether it can serve for training purposes, it has
been evaluated on a corpus of dierent genre (formal ver-
sus informal). Therefore, we foresee that DrugSemantic
will be useful for the development and testing of Spanish
NE recognition tools in the pharmacotherapeutic domain.
As future work, we will study an extrinsic evaluation of a
NERC system trained on DrugSemantics and its contribu-
tion to other NLP systems (such as question answering or
other information extraction tools). Besides, we will con-
sider the extension of DrugSemantics to other NLP tasks
(e.g. relation extraction or negation). Finally, we plan to
enhance our dictionaries driven by the precision analysis.
Conict of interest
The authors report that there are no conicts of interest.
Acknowledgements
Funding: This work was supported by the Spanish
Government (grants number TIN2015-65100-R; TIN2015-
65136-C02-2-R), the Generalitat Valenciana (grant num-
ber PROMETEOII/2014/001) and the BBVA Foundation
(award number FUNDACIONBBVA2-16PREMIOI).
The authors would like to thank the team of annotators
for their time and work during the annotation of this cor-
pus, as well as Maria Rey Gilabert for her pharmacothera-
peutic knowledge. Thanks to the anonymous reviewers for
their suggestions which have helped to improve this work.
References
[1] C. Friedman, T. C. Rindesch, M. Corn, Natural lan-
guage processing: state of the art and prospects for signif-
icant progress, a workshop sponsored by the National Li-
brary of Medicine, J. Biomed. Inform. 46 (5) (2013) 765{773.
doi:10.1016/j.jbi.2013.06.004.
[2] PubMed.
URL http://www.ncbi.nlm.nih.gov/pubmed/(accessed:10.
01.2017)
[3] A. Gonzalez-Gonzalez, E. Escortell Mayor, T. Hernandez
Fernandez, J. Sanchez Mateos, T. Sanz Cuesta, R. Riesgo
Fuertes, Necesidades de informacion de los medicos de atencion
23
  
primaria: analisis de preguntas y su resolucion, Aten. Prim.
35 (8) (2005) 419{431.
[4] Scopus.
URL http://www.scopus.com/(accessed:10.01.2017)
[5] K. Roberts, M. Simpson, D. Demner-Fushman, E. Voorhees,
W. Hersh, State-of-the-art in biomedical literature retrieval for
clinical cases: a survey of the TREC 2014 CDS track, Inf. Retr.
19 (1-2) (2016) 113{148. doi:10.1007/s10791-015-9259-x.
[6] G. Del Fiol, T. Workman, P. Gorman, Clinical ques-
tions raised by clinicians at the point of care: A system-
atic review, JAMA Intern. Med. 174 (5) (2014) 710{718.
doi:10.1001/jamainternmed.2014.368.
[7] A. I. Gonzalez-Gonzalez, J. Sanchez Mateos, T. Sanz Cuesta,
R. Riesgo Fuertes, E. Escortell Mayor, T. Hernandez Fernandez,
Estudio de las necesidadesde informacion generadas por los
medicos de atencion primaria (proyecto ENIGMA)*, Aten.
prim. 38 (4) (2006) 219{224.
[8] G. Del Fiol, A. I. Weber, C. P. Brunker, C. R. Weir, Clini-
cal questions raised by providers in the care of older adults:
a prospective observational study, BMJ Open 4 (7) (2014).
doi:10.1136/bmjopen-2014-005315.
[9] S. Doan, M. Conway, T. M. Phuong, L. Ohno-Machado, Natural
language processing in biomedicine: a unied system architec-
ture overview, Methods in Mol. Biol. (Clifton, N.J.) 1168 (2014)
275{294. doi:10.1007/978-1-4939-0847-9 16.
[10] C. D. Manning, P. Raghavan, H. Schutze, Introduction to In-
formation Retrieval, Cambridge University Press, Cambridge,
2008. doi:10.1017/CBO9780511809071.
[11] R. Feldman, J. Sanger, The text mining handbook: advanced
approaches in analyzing unstructured data, Cambridge Univer-
sity Press, New York, 2007. doi:10.1017/CBO9780511546914.
[12] M. Ben-dov, R. Feldman, Text Mining and Information Ex-
traction, in: O. Maimon, L. Rokach (Eds.), Data Mining and
Knowledge Discovery Handbook, 2nd Edition, Springer US,
Boston, MA, 2010, Ch. 42, pp. 809{835. doi:10.1007/978-0-
387-09823-4 42.
[13] M. A. Hearst, Untangling text data mining, in: Proceedings
of the 37th Annual Meeting of the Association for Computa-
tional Linguistics on Computational Linguistics, Association
for Computational Linguistics, Stroudsburg, 1999, pp. 3{10.
doi:10.3115/1034678.1034679.
[14] A. Singhal, Modern information retrieval: A brief overview,
IEEE Data Eng. Bull. 24 (2001) 35{43.
[15] Google.
URL http://www.google.com(accessed:10.01.2017)
[16] W. J. Wilbur, A. Rzhetsky, H. Shatkay, New directions in
biomedical text annotation: denitions, guidelines and corpus
construction, BMC Bioinform. 7 (2006) 356. doi:10.1186/1471-
2105-7-356.
[17] W. W. Chapman, P. M. Nadkarni, L. Hirschman, L. W.
D'Avolio, G. K. Savova, O. Uzuner, Overcoming barriers to
NLP for clinical text: the role of shared tasks and the need for
additional creative solutions., JAMIA 18 (5) (2011) 540{543.
doi:10.1136/amiajnl-2011-000465.
[18] K. Bretonnel Cohen, D. Demner-Fushman, Biomedical Natu-
ral Language Processing, Vol. 11 of Natural Language Process-
ing, John Benjamins Publishing Company, Amsterdam, 2014.
doi:10.1075/nlp.11.
[19] J. W. Ely, J. A. Oshero, M. H. Ebell, G. R. Bergus, B. T.
Levy, M. Chambliss, E. R. Evans, Analysis of questions asked
by family doctors regarding patient care, Br. Med. J. 319 (1999)
358{361.
[20] M. Oronoz, K. Gojenola, A. Perez, A. D. de Ilarraza, A. Casillas,
On the creation of a clinical gold standard corpus in Spanish:
Mining adverse drug reactions, J. Biomed. Inform. 56 (2015)
318{332. doi:10.1016/j.jbi.2015.06.016.
[21] E. M. van Mulligen, A. Fourrier-Reglat, D. Gurwitz,
M. Molokhia, A. Nieto, G. Triro, J. a. Kors, L. I. Furlong,
The EU-ADR corpus: annotated drugs, diseases, targets, and
their relationships, J. Biomed. Inform. 45 (5) (2012) 879{884.
doi:10.1016/j.jbi.2012.04.004.
[22] R. I. Dogan Doan, R. Leaman, Z. Lu, NCBI disease cor-
pus: a resource for disease name recognition and con-
cept normalization, J. Biomed. Inform. 47 (2014) 1{10.
doi:10.1016/j.jbi.2013.12.006.
[23] A. Roberts, R. Gaizauskas, M. Hepple, G. Demetriou, Y. Guo,
I. Roberts, A. Setzer, Building a semantically annotated cor-
pus of clinical texts, J. Biomed. Inform. 42 (5) (2009) 950{966.
doi:10.1016/j.jbi.2008.12.013.
[24] M. Herrero-Zazo, I. Segura-Bedmar, P. Martinez, T. Declerck,
The DDI corpus: An annotated corpus with pharmacologi-
cal substances and drug-drug interactions, J. Biomed. Inform.
46 (5) (2013) 914{920. doi:10.1016/j.jbi.2013.07.011.
[25] O. Uzuner, I. Solti, E. Cadag, Extracting medication infor-
mation from clinical text, JAMIA 17 (5) (2010) 514{518.
doi:10.1136/jamia.2010.003947.
[26] O. Uzuner, I. Solti, F. Xia, E. Cadag, Community an-
notation experiment for ground truth generation for the
i2b2 medication challenge, JAMIA 17 (5) (2010) 519{523.
doi:10.1136/jamia.2010.004200.
[27] O. Uzuner, B. R. South, S. Shen, S. L. DuVall, 2010 i2b2/VA
challenge on concepts, assertions, and relations in clinical
text, JAMIA 18 (5) (2011) 552{556. doi:10.1136/amiajnl-2011-
000203.
[28] T. Lingren, L. Deleger, K. Molnar, H. Zhai, J. Meinzen-Derr,
M. Kaiser, L. Stoutenborough, Q. Li, I. Solti, Evaluating the
24
  
impact of pre-annotation on annotation speed and potential
bias: natural language processing gold standard development
for clinical named entity recognition in clinical trial announce-
ments, JAMIA 21 (3) (2014) 406{413. doi:10.1136/amiajnl-
2013-001837.
[29] Q. Li, L. Deleger, T. Lingren, H. Zhai, M. Kaiser, L. Stouten-
borough, A. G. Jegga, K. B. Cohen, I. Solti, Mining FDA drug
labels for medical conditions, BMC Med. Inform. Decis. Making
13 (1) (2013). doi:10.1186/1472-6947-13-53.
[30] S. Pradhan, N. Elhadad, W. W. Chapman, S. Manandhar,
G. Savova, SemEval-2014 Task 7: Analysis of Clinical Text,
Proceedings of the 8th International Workshop on Semantic
Evaluation (2014) 54{62.
[31] B. Rosario, M. Hearst, Classifying semantic relations in
bioscience texts, Proceedings of the 42nd Annual Meeting
on Association for Computational Linguistics (2004) 430{
437doi:10.3115/1218955.1219010.
[32] H. Gurulingappa, A. M. Rajput, A. Roberts, J. Fluck,
M. Hofmann-Apitius, L. Toldo, Development of a benchmark
corpus to support the automatic extraction of drug-related ad-
verse eects from medical case reports, J. Biomed. Inform.
45 (5) (2012) 885{892. doi:10.1016/j.jbi.2012.04.008.
[33] A. Patki, A. Sarker, P. Pimpalkhute, A. Nikfarjam, R. Ginn,
Mining Adverse Drug Reaction Signals form Social Media: Go-
ing Beyond Extraction, in: Proceedings of BioLinkSig, 2014,
pp. 9{19.
[34] K. W. Fung, C. S. Jao, D. Demner-Fushman, Extracting drug
indication information from structured product labels using
natural language processing, JAMIA 20 (3) (2013) 482{488.
doi:10.1136/amiajnl-2012-001291.
[35] N. Elhadad, S. Pradhan, S. L. Gorman, S. Manandhar, W. W.
Chapman, G. Savova, SemEval-2015 Task 14 : Analysis of Clin-
ical Text, in: Proceedings of the 9th International Workshop on
Semantic Evaluation (SemEval 2015), 2015, pp. 303{310.
[36] D. S. Wishart, C. Knox, A. C. Guo, S. Shrivastava, M. Has-
sanali, P. Stothard, Z. Chang, J. Woolsey, DrugBank: a com-
prehensive resource for in silico drug discovery and exploration,
Nucleic Acids Res. 34 (Database issue) (2006) D668{D672.
doi:10.1093/nar/gkj067.
[37] I. Segura-Bedmar, R. Revert, P. Martnez, Detecting drugs and
adverse events from Spanish health social media streams, in:
Proceedings of the 5th International Workshop on Health Text
Mining and Information Analysis, 2014, pp. 106{115.
[38] ForumClinic.
URL http://www.forumclinic.org/(accessed:10.01.2017)
[39] B. R. South, D. Mowery, Y. Suo, J. Leng, O. Ferrandez, S. M.
Meystre, W. W. Chapman, Evaluating the eects of machine
pre-annotation and an interactive annotation interface on man-
ual de-identication of clinical text, J. Biomed. Inform. 50
(2014) 162{172. doi:10.1016/j.jbi.2014.05.002.
[40] Real Decreto 1345/2007, de 11 de octubre, por el que se reg-
ula el procedimiento de autorizacion, registro y condiciones de
dispensacion de los medicamentos de uso humano fabricados
industrialmente (2007).
[41] G. Martn, F. J. Morales-Olivas, Nuevos lenguajes informaticos
en la difusion de informacion sobre medicamentos, Med. Clin.
(Barc) 128 (13) (2007) 498{503. doi:10.1157/13100938.
[42] S. Rubrichi, S. Quaglini, Summary of Product Characteristics
content extraction for a safe drugs usage, J. Biomed. Inform.
45 (2) (2012) 231{239. doi:10.1016/j.jbi.2011.10.012.
[43] Ley 14/1986, de 25 de abril, General de Sanidad. (1986).
[44] Ley Organica 15/1999, de 13 de diciembre, de Proteccion de
Datos de Caracter Personal. (1999).
[45] Ley 41/2002, de 14 de noviembre, basica reguladora de la au-
tonoma del paciente y de derechos y obligaciones en materia de
informacion y documentacion clnica (2002).
[46] R. Nalichowski, D. Keogh, H. C. Chueh, S. N. Murphy, Calcu-
lating the benets of a Research Patient Data Repository, in:
AMIA Annual Symposium proceedings, 2006, p. 1044.
[47] CIMA (Centro de Informacion online de Medicamentos de la
AEMPS).
URL http://www.aemps.gob.es/cima/(accessed:10.01.2017)
[48] M. T. Roma-Ferri, OntoFIS: tecnologa ontologica en el do-
minio farmacoterapeutico, Ph.D. thesis, Universidad de Ali-
cante (2009).
[49] W. Shrank, J. Avorn, C. Rolon, P. Shekelle, Eect of content
and format of prescription drug labels on readability, under-
standing, and medication use: a systematic review, Ann. Phar-
macother. 41 (5) (2007) 783{801. doi:10.1345/aph.1H582.
[50] Real Decreto 1348/2003, de 31 de octubre, por el que se adapta
la clasicacion anatomica de medicamentos al sistema de clasi-
cacion ATC. (2003).
[51] WHO Collaborating Center for Drug Statistics Methodology,
ATC/DDD.
URL http://www.whocc.no/atc/(accessed:10.01.2017)
[52] U. G. P. Oce, Food and Drugs, 21CFR3.2 (2016).
URL https://www.accessdata.fda.gov/scripts/cdrh/
cfdocs/cfcfr/CFRSearch.cfm?fr=3.2(accessed:10.01.2017)
[53] H. Cunningham, D. Maynard, K. Bontcheva, V. Tablan,
N. Aswani, I. Roberts, G. Gorrell, A. Funk, A. Roberts,
D. Damljanovic, T. Heitz, M. Greenwood, H. Saggion, J. Pe-
trak, Y. Li, W. Peters, E. Al, Developing Language Processing
Components with GATE Version 7 (a User Guide), 2012.
[54] WHO Collaborating Center for Drug Statistics Methodology,
Guidelines for ATC classication and DDD assignment 2016,
Oslo, 2016.
25
  
URL http://www.whocc.no/filearchive/publications/2016_
guidelines_web.pdf(accessed:10.01.2017)
[55] The Cochrane Collaboration, Assessing risk of bias in included
studies, in: Julian PT Higgins and Sally Green (Ed.), Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 [updated March 2011], 2011, Ch. 8.
URL http://handbook.cochrane.org/chapter_8/8_
assessing_risk_of_bias_in_included_studies.htm
[56] R. Artstein, M. Poesio, Inter-Coder Agreement for Computa-
tional Linguistics, Comput. Linguist. 34 (4) (2008) 555{596.
doi:10.1162/coli.07-034-R2.
[57] G. Hripcsak, A. S. Rothschild, Agreement, the f-measure, and
reliability in information retrieval, JAMIA 12 (3) (2005) 296{
298. doi:10.1197/jamia.M1733.
[58] F. D. B. Navarro Colorado, Metodologa, construccion y ex-
plotacion de corpus anotados semantica y anaforicamente,
Ph.D. thesis, University of Alicante (2007).
[59] J. Lei, B. Tang, X. Lu, K. Gao, M. Jiang, H. Xu, A compre-
hensive study of named entity recognition in Chinese clinical
text, JAMIA 21 (5) (2014) 808{814. doi:10.1136/amiajnl-2013-
002381.
[60] J. R. Landis, G. G. Koch, The measurement of observer
agreement for categorical data., Biom. 33 (1) (1977) 159{174.
doi:10.2307/2529310.
[61] I. Moreno, P. Moreda, M. Roma-Ferri, Reconocimiento de en-
tidades nombradas en dominios restringidos, in: Actas del III
Workshop en Tecnologas de la Informatica, Alicante, Spain,
2012, pp. 41{57.
[62] I. Moreno, P. Moreda, M. Roma-Ferri, MaNER: a MedicAl
Named Entity Recogniser for Spanish, in: C. Biemann, S. Hand-
schuh, A. Freitas, F. Meziane, E. Metais (Eds.), 20th Interna-
tional Conference on Applications of Natural Language to Infor-
mation Systems, Springer International Publishing Switzerland,
Passau, 2015, pp. 418{423. doi:10.1007/978-3-319-19581-0 40.
[63] I. Moreno, P. Moreda, M. T. Roma-Ferri, Estudio de abilidad
y viabilidad de la Web 2.0 y la Web semantica para enriquecer
lexicones en el dominio farmacologico, Proces. Leng. Nat. 55
(2015) 65{72.
[64] J. Garca, EURO-E (2009).
URL http://histolii.ugr.es/euroe/e_index.
html(accessed:10.01.2017)
[65] BEDCA (Base de Datos Espaola de Composicion de Alimentos).
URL http://www.bedca.net/(accessed:10.01.2017)
[66] Direccion General de Farmacia y Productos Sanitarios. MSSSI.
Spanish Government, DIGITALIS (Nomenclator Digitialis)
(2011).
URL http://www.msc.es/profesionales/nomenclator.
do(accessed:10.01.2017)
[67] IHTSDO, SNOMED Clinical Terms User Guide, 2014th Edi-
tion, 2010.
URL http://www.snomed.org/ug.pdf(accessed:10.01.2017)
[68] Moreno, Isabel and Roma-Ferri, M.T. and Moreda, Paloma,
Named Entity Classication based on Proles: a Domain In-
dependent Approach, in: 22th International Conference on Ap-
plications of Natural Language to Information Systems, Liege,
2017 - in press.
[69] I. Moreno, M. T. Roma-Ferri, P. Moreda, Propuesta de un sis-
tema de clasicacion de entidades basado en perles e indepen-
diente del dominio, Proces. Leng. Nat. 59 (2017) { Submitted.
[70] I. Moreno, M. T. Roma-Ferri, P. Moreda, Proposal for a Lan-
guage Independent Named Entity Classication System based
on Proles, in: Proceedings of the 15th International Confer-
ence Text, Speech and Dialogue, 2017 - Submitted.
[71] I. Moreno, E. Boldrini, P. Moreda, M. T. Roma-Ferri,
DrugSemantis Gold Standard: an annotated corpus of
Spanish Summaries of Product Characteristics anno-
tated for pharmacotherapeutic named entity recogni-
tion, https://data.mendeley.com/datasets/fwc7jrc5jr/
draft?a=48099c59-ac0d-4366-875e-7ec38b8534b8 (2017).
doi:doi:10.17632/fwc7jrc5jr.1.
[72] L. Deleger, Q. Li, T. Lingren, M. Kaiser, K. Molnar, L. Stouten-
borough, M. Kouril, K. Marsolo, I. Solti, Building gold stan-
dard corpora for medical natural language processing tasks., in:
Proceedings of AMIA Annual Symposium, Vol. 2012, 2012, pp.
144{153.
[73] W. W. Chapman, J. N. Dowling, G. Hripcsak, Evalua-
tion of training with an annotation schema for manual
annotation of clinical conditions from emergency depart-
ment reports, Int. J. Med. Inform. 77 (2) (2008) 107{113.
doi:10.1016/j.ijmedinf.2007.01.002.
[74] A. Cocos, T. Qian, C. Callison-Burch, A. J. Masino, Crowd con-
trol: Eectively utilizing unscreened crowd workers for biomed-
ical data annotation, J. Biomed. Inform. 69 (2017) 86{92.
doi:10.1016/j.jbi.2017.04.003.
[75] Y. Lou, S. W. Tu, C. Nyulas, T. Tudorache, R. J. Chalmers,
M. A. Musen, Use of ontology structure and bayesian models
to aid the crowdsourcing of icd-11 sanctioning rules, J. Biomed.
Inform. 68 (2017) 20 { 34. doi:10.1016/j.jbi.2017.02.004.
[76] M. Sabou, K. Bontcheva, L. Derczynski, A. Scharl, Corpus An-
notation through Crowdsourcing: Towards Best Practice Guide-
lines, in: Proceedings of the Ninth International Conference on
Language Resources and Evaluation, 2014, pp. 859{866.
[77] M. R. Costa-Jussa, M. Farrus, J. S. Pons, Machine Translation
in Medicine A quality analysis of statistical machine transla-
tion in the medical domain, in: Advanced Research in Scientic
Areas, 2012, pp. 1995{1998.
26
  
Graphical Abstract
  
+ DrugSemantics Corpus is a set of Spanish Summary of Product 
Characteristics 
+ 10 pharmacotherapeutic named entity types manually annotated by 3 
annotators 
+ Corpus Quality: substantial reliability(79.33%), almost perfect 
precision(94.65%) 
+ Quality confirmed through statistical hypothesis testing using Z-test 
in both cases 
+ Precison ensured via semiautomatic method that enhances MaNER, 
dictionary-based NER 
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